These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4406591)

  • 61. Bone isoenzyme of serum alkaline phosphatase and urinary hydroxyproline excretion in thyrotoxicosis.
    Broulik PD; Stĕpán JJ; Límanová Z; Pacovský V
    Endocrinol Exp; 1985 Sep; 19(3):165-9. PubMed ID: 3876205
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Attempts to prevent disuse osteoporosis by treatment with calcitonin, longitudinal compression and supplementary calcium and phosphate.
    Hantman DA; Vogel JM; Donaldson CL; Friedman R; Goldsmith RS; Hulley SB
    J Clin Endocrinol Metab; 1973 May; 36(5):845-58. PubMed ID: 4698244
    [No Abstract]   [Full Text] [Related]  

  • 63. Human calcitonin in the treatment of Paget's bone disease.
    Woodhouse NJ; Bordier P; Fisher M; Joplin GF; Reiner M; Kalu DN; Foster GV; MacIntyre I
    Lancet; 1971 Jun; 1(7710):1139-43. PubMed ID: 4102856
    [No Abstract]   [Full Text] [Related]  

  • 64. Synthetic salmon calcitonin. Treatment of Paget's disease and osteogenesis imperfecta.
    Goldfield EB; Braiker BM; Prendergast JJ; Kolb FO
    JAMA; 1972 Sep; 221(10):1127-9. PubMed ID: 4679000
    [No Abstract]   [Full Text] [Related]  

  • 65. Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia.
    Bell NH; Avery S; Johnston CC
    J Clin Endocrinol Metab; 1970 Sep; 31(3):283-90. PubMed ID: 4916538
    [No Abstract]   [Full Text] [Related]  

  • 66. [X-ray diagnosis of metastases of cancer of the prostate into the bones].
    Perel'man VM; Chechenin MG
    Urol Nefrol (Mosk); 1974; 39(4):55-7. PubMed ID: 4411542
    [No Abstract]   [Full Text] [Related]  

  • 67. [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
    Polico C; Nascimben O; Maccari F; Fazzin G
    Quad Sclavo Diagn; 1978 Dec; 14(4):486-93. PubMed ID: 757622
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The value of the calcitonin test in Paget's disease of bone].
    D'Amore M; Bozzi A; Telesca ML; Carrozzo M
    Minerva Med; 1981 Apr; 72(14):865-8. PubMed ID: 7219796
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.
    Shai F; Baker RK; Wallach S
    J Clin Invest; 1971 Sep; 50(9):1927-40. PubMed ID: 4935444
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of Paget's disease of bone with porcine calcitonin: clinical and metabolic responses.
    Kanis JA; Fitzpatrick K; Strong JA
    Q J Med; 1975 Jul; 44(175):399-413. PubMed ID: 1101286
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Paget's disease of bone: problems and management.
    Haddad JG
    Orthop Clin North Am; 1972 Nov; 3(3):775-86. PubMed ID: 4344935
    [No Abstract]   [Full Text] [Related]  

  • 72. The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate.
    Morales A; Burr RC; Bruce AW
    Can Med Assoc J; 1970 Aug; 103(4):372-3. PubMed ID: 5447717
    [No Abstract]   [Full Text] [Related]  

  • 73. [Calcitonin nasal spray for Paget's disease of the bone].
    Luboshitzky R; Bar-Shalom R
    Harefuah; 1995 Mar; 128(6):358-62, 399. PubMed ID: 7750816
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis.
    Pietschmann P; Resch H; Krexner E; Woloszczuk W; Willvonseder R
    Acta Med Austriaca; 1991; 18(5):114-6. PubMed ID: 1796722
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
    Stĕpán JJ; Mikulecký M; Bek V; Broulík P; Pacovský V
    Neoplasma; 1989; 36(4):495-501. PubMed ID: 2770935
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Diagnostic significance of the level of hydroxyproline excretion in myeloma multiplex].
    Radom S; Wieraszko-Burzyńska E; Zulawski M
    Nowotwory; 1969; 19(3):173-80. PubMed ID: 5370331
    [No Abstract]   [Full Text] [Related]  

  • 77. [Problems concerning clinical application of calcitonin].
    Morii H
    Nihon Rinsho; 1972 Mar; 30(3):759-65. PubMed ID: 4556796
    [No Abstract]   [Full Text] [Related]  

  • 78. Salmon and porcine calcitonin treatment of Paget's disease of bone.
    Avramides A
    Clin Orthop Relat Res; 1977; (127):78-85. PubMed ID: 303164
    [No Abstract]   [Full Text] [Related]  

  • 79. Acute responsiveness to calcitonin in chronic renal failure.
    Cochran M; Hillyard CJ; Dew GJ; Martin TJ
    Br Med J; 1976 Aug; 2(6032):396-8. PubMed ID: 947443
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Metabolic effects of pamidronate in patients with metastatic bone disease.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.